Can a pill that starves tumors of oxygen help fight advanced cancer?
NCT ID NCT02974738
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to find the safest dose and see how the body handles the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- belzutifan (a HIF-2α inhibitor drug)
- What this could lead to
- If successful, this could lead to a new treatment option for advanced solid tumors, including kidney cancer and glioblastoma.
- What could go wrong
- This is an early phase 1 trial, so the drug may not work or could cause serious side effects. The goal is primarily to find a safe dose, not to prove effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a new infusion drug tame advanced solid tumors?
- Can a radioactive injection target bone tumors? a Dose-Finding trial aims to find out